A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Res
Main Authors: Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu
Formato: Artigo
Idioma:Inglês
Publicado em: Cognizant Communication Corporation 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://ncbi.nlm.nih.gov/pubmed/29321093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15151523767752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados